Clinical Trial: NCT03965468
Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | ETOP IBCSG Partners Foundation |
| Information Provided By: | ETOP IBCSG Partners Foundation |
| Last Update Posted: | 2026-10-05 |
Study Overview
Brief Summary
A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy plus stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the locoregional primary tumour, in patients with histologically-confirmed synchronous oligo-metastatic non-small cell lung cancer (NSCLC).
Official Title
A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer, Stage IV, Oligometastasis
Intervention / Treatment
- Drug: Durvalumab
- Drug: Carboplatin
- Drug: Paclitaxel
- Radiation: Stereotactic body radiation therapy (SBRT)
- Procedure: Surgical resection - definitive local treatment.
- Radiation: Radical radiotherapy - definitive local treatment.
- Drug: Tremelimumab
Other Study ID Numbers
- ETOP 14-18
- 2018-003011-22
- ESR-17-13224
- 2018
Start Date (Actual)
2019-11-19
Primary Completion Date (Estimated)
2026-12
Study Completion Date (Estimated)
2026-12
Enrollment (Estimated)
96
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | ETOP IBCSG Partners Foundation |
| Information Provided By: | ETOP IBCSG Partners Foundation |
| Last Update Posted: | 2026-10-05 |
Study Overview
Brief Summary
A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy plus stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the locoregional primary tumour, in patients with histologically-confirmed synchronous oligo-metastatic non-small cell lung cancer (NSCLC).
Official Title
A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer, Stage IV, Oligometastasis
Intervention / Treatment
- Drug: Durvalumab
- Drug: Carboplatin
- Drug: Paclitaxel
- Radiation: Stereotactic body radiation therapy (SBRT)
- Procedure: Surgical resection - definitive local treatment.
- Radiation: Radical radiotherapy - definitive local treatment.
- Drug: Tremelimumab
Other Study ID Numbers
- ETOP 14-18
- 2018-003011-22
- ESR-17-13224
- 2018
Start Date (Actual)
2019-11-19
Primary Completion Date (Estimated)
2026-12
Study Completion Date (Estimated)
2026-12
Enrollment (Estimated)
96
Study Type
Interventional
Phase
Phase 2